Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encaleret versus standard of care in adults with autosomal dominant hypocalcemia type 1
NL-OMON59765Phase 3Active, not recruiting
- Sponsor
- Calcilytix Therapeutics
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in autosomal dominant hypocalcemia type 1 (ADH1) comparing Encaleret arm with Standard of care arm (2 arms). Primary endpoint: Responder status. Started Jul 2024; status: active, not recruiting.
02
Drugs
encaleret
03
Conditions
autosomal dominant hypocalcemia type 1 (ADH1)
Beyond the preview
Go deeper on NL-OMON59765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59765.